Evidence map›Paper›PMID 40980587›Full record

ArticleOpen forum infectious diseases2025

Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy.

Rinki Deo, Manish C Choudhary, Owen T Glover, Rachel Bender Ignacio, Julie Boucau, Kara W Chew, Carlee Moser, Judith S Currier, Joseph J Eron, Arzhang Cyrus Javan and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Rinki DeoBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Manish C ChoudharyBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Owen T GloverRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, Massachusetts, USA.
Rachel Bender IgnacioUniversity of Washington, Seattle, Washington, USA.
Julie BoucauRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6731-7238
Kara W ChewDavid Geffen School of Medicine, UCLA, Los Angeles, California, USA.
Carlee MoserHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-5601-9112
Judith S CurrierDavid Geffen School of Medicine, UCLA, Los Angeles, California, USA.
Joseph J EronUNC School of Medicine, Chapel Hill, North Carolina, USA.
Arzhang Cyrus JavanNational Institutes of Health, Bethesda, Maryland, USA.
Mark J GigantiHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Evgenia AgaHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Michael GibbsVaccines and Immunotherapies, AstraZeneca, Cambridge, UK.
Taylor CohenVaccines and Immunotherapies, AstraZeneca, Gaithersburg, USA.
Katie StreicherVaccines and Immunotherapies, AstraZeneca, Gaithersburg, USA.
Karina SobolevaVaccines and Immunotherapies, AstraZeneca, Gaithersburg, USA.
Courtney V FletcherUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.
Eric S DaarLundquist Institute, Harbor-UCLA Medical Center, Los Angeles, California, USA.
Alexander L GreningerUniversity of Washington, Seattle, Washington, USA.
Robert W CoombsUniversity of Washington, Seattle, Washington, USA.
William FischerUNC School of Medicine, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-4900-098X
Michael D HughesHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Davey SmithUniversity of California San Diego, San Diego, California, USA.
David Alain WohlUNC School of Medicine, Chapel Hill, North Carolina, USA.
Amy K BarczakRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, Massachusetts, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
NIAID NIH HHS U01 AI038855NIAID NIH HHS U01 AI038858NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

We evaluated intramuscular (IM) versus intravenous (IV) administration of tixagevimab/cilgavimab in early COVID-19. Both routes achieved rapid elimination of culturable virus and minimal emergence of resistance. These results support IM delivery as a viable alternative to IV, with important implications for scalable deployment in future viral pandemics.

Indexed as

intramuscular administrationmonoclonal antibodiesSARS-CoV-2tixagevimab/cilgavimabviral culture conversion

Identifiers

PMID40980587
PMCPMC12449731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.